Nj State Employees Deferred Compensation Plan Halozyme Therapeutics, Inc. Transaction History
Nj State Employees Deferred Compensation Plan
- $823 Million
- Q2 2025
A detailed history of Nj State Employees Deferred Compensation Plan transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Nj State Employees Deferred Compensation Plan holds 27,800 shares of HALO stock, worth $1.75 Million. This represents 0.18% of its overall portfolio holdings.
Number of Shares
27,800
Previous 27,800
-0.0%
Holding current value
$1.75 Million
Previous $1.77 Million
18.44%
% of portfolio
0.18%
Previous 0.23%
Shares
8 transactions
Others Institutions Holding HALO
# of Institutions
582Shares Held
122MCall Options Held
308KPut Options Held
186K-
Black Rock Inc. New York, NY17.6MShares$1.11 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$807 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$381 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$245 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$231 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.76B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...